GlobeNewswire

Nexstim Plc: Managers’ Transactions

Share

Company announcement, Helsinki, 29 March 2021 at 12 pm (EEST)

Nexstim Plc: Managers’ Transactions

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces managers’ transactions as follows:

Person subject to the notification requirement
Name: Forss Martin
Position: Member of the Board/Deputy member
Issuer: Nexstim Oyj
LEI: 743700S7ZI0LNMHZ6Y27

Notification type: INITIAL NOTIFICATION
Reference number: 743700S7ZI0LNMHZ6Y27_20210326151605_2
____________________________________________

Transaction date: 2021-03-24
Venue: FIRST NORTH FINLAND (FNFI)
Instrument type: SHARE
ISIN: FI4000480470
Nature of the transaction: SUBSCRIPTION

Transaction details
(1): Volume: 133,533 Unit price: .03 EUR

Aggregated transactions
(1): Volume: 133,533 Volume weighted average price: .03 EUR
____________________________________________

Transaction date: 2020-04-06
Venue: FIRST NORTH FINLAND (FNFI)
Instrument type: SHARE
ISIN: FI4000480470
Nature of the transaction: EXERCISE (RIGHTS, PUT AND CALL OPTIONS)
(X) Linked to stock option programme

Transaction details
(1): Volume: 17,067 Unit price: .26 EUR

Aggregated transactions
(1): Volume: 17,067 Volume weighted average price: .26 EUR
____________________________________________

Transaction date: 2020-05-20
Venue: FIRST NORTH FINLAND (FNFI)
Instrument type: SHARE
ISIN: FI4000480470
Nature of the transaction: ACQUISITION

Transaction details
(1): Volume: 250,000 Unit price: .0176 EUR

Aggregated transactions
(1): Volume: 250,000 Volume weighted average price: .0176 EUR

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

Erik Penser Bank AB (Certified Adviser)                          
 +46 8 463 83 00
certifiedadviser@penser.se

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

REC Silicon - Notice of Annual General Meeting20.4.2021 15:12:01 CEST | Press release

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Lysaker, Norway - April 20, 2021: Notice is hereby given that the Annual General Meeting of REC Silicon ASA (REC) will be held at the offices of Schjødt, Ruseløkkveien 14, Oslo, Norway on May 11, 2021 at 4.00 pm CET. Please find attached Notice of the General Meeting and the Recommendation of the Nomination Committee. All documents are available at https://www.recsilicon.com/investors/agm/ Due to the extraordinary situation with Covid-19, and in light of prevailing travel and meeting recommendations and restrictions, the Board urges shareholders to vote through submission of proxy forms prior to the meeting and not attend the meeting in person. For further information, please contact: James A. May II, Chief Financial Officer Phone: +1 509 989 1023 Email: james.may@recsilicon.com Nils O. Kjerstad, IR Contact Phone: +47 9135 6659 Email: nils.kjerstad@crux.no About REC

Årsredovisning 2020 är nu publicerad20.4.2021 15:00:00 CEST | Pressemelding

2021-04-20 PRESSRELEASE Årsredovisning 2020är nu publicerad Arcoma publicerar idag sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.arcoma.se/about-us/investors. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Adviser är Erik Penser Bank (tel: 08-4638300, e-mail: certifiedadviser@penser.se) För mer information om bolaget besök www.arcoma.se För ytterligare information, vänligen kontakta: Arcomas VD Sanna Rydbe

Skyharbour’s Partner Company Valor Completes Airborne Survey at Hook Lake Uranium Project, Saskatchewan20.4.2021 14:00:00 CEST | Press release

VANCOUVER, British Columbia, April 20, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) is pleased to announce that partner company Valor Resources Limited (“Valor”) entered into a contract with Precision GeoSurveys Inc. through TerraLogic Exploration Inc. (“TerraLogic”), the Company’s geological consultants, to undertake a detailed airborne survey over the Hook Lake Project (previously North Falcon Point). The survey commenced in early April 2021 and is now complete. TerraLogic designed the low-level airborne magnetic and VLF-EM survey to cover the entire Hook Lake claim area, using a fixed-wing aircraft, at 75m line-spacing totaling 5,100 line-km. Final data processing, data interpretation, target selection and recommendations for follow-up ground-based exploration and drilling programs will also be handled by TerraLogic. This process is expected to take approximately six weeks, followed immediately by the recommended fi

Acarix publicerar årsredovisningen för 202020.4.2021 13:00:00 CEST | Pressemelding

Pressmeddelande Malmö, 20 april 2021 Acarix publicerar årsredovisningen för 2020 Idag, tisdagen den 20 april, publicerar Acarix sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.acarix.com. Årsredovisningen finns även bifogad i pressreleasen. För mer information, vänligen kontakta: Per Persson, vd, e-mail: per.persson@acarix.com, telefon: +46 73 600 59 90 Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande vid den tidpunkt som anges av företagets nyhetsdistributör, GlobeNewswire. Om Acarix Acarix grundades 2009 och är noterat på Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix CADScor®System använder en avancerad sensor som placeras på huden ovanför hjärtat för att lyssna på ljudet av hjärtkontraktion och turbulent flöde. Det har utformats för att vara ett allt-i-ett-system i den meningen att signalen från hjärtat spelas in, bearbetas och visas som en patientspecifik s k CAD-score på skärmen. Presentation av mätresul

Acarix publishes the annual report for 202020.4.2021 13:00:00 CEST | Press release

Press release Malmö, Sweden, April 20, 2021 Acarix publishes the annual report for 2020 Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release. For further information, please contact: Per Persson, CEO, E-mail: per.persson@acarix.com, Phone: +46 73 600 59 90 The information was provided, through the agency of the above contact person, for publication at the time specified by the company's news distributor, GlobeNewswire. About Acarix: Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the devi

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex20.4.2021 12:30:00 CEST | Press release

– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3– LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication for GW’s cannabidiol in Europe, paves the way for the expanded launch of the medicine across Europe. “This is an exciting moment for patients, and their families, who are affected by this debilitating disease and may benefit from this treatment. This approval is

Fingerprint Cards AB: invitation to the first quarter 2021 results presentation20.4.2021 11:30:00 CEST | Press release

Fingerprint Cards AB (Fingerprints™) will host a telephone conference and webcast presentation of its first quarter 2021 results, on April21, 2021 at 09:00 CEST. Fingerprints’ CEO Christian Fredrikson will present the report together with CFO Per Sundqvist in a combined webcast and telephone conference. The presentation will be held in English. Time: Wednesday, April 21, 2021 at 09:00 am CEST. Location: combined webcast and telephone conference. The report is available at https://www.fingerprints.com/ The webcast and the presentation material can be accessed through https://edge.media-server.com/mmc/p/5dpwm66j where it is also possible to ask questions. For media and analysts: The telephone conference dial-in is +44 (0) 2071 928000 (international participants) or 08-506 921 80 (Swedish participants). Please state conference ID 9862978. About Fingerprints Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and se